Kimberly-Clark sells majority stake of $3.4 billion international tissue unit to Brazil's Suzano

Kimberly-Clark has agreed to sell a 51% stake in its international tissue business to Suzano for $1.73 billion in cash, valuing the entire business at $3.4 billion; the transaction, expected to close in mid-2026, will form a joint venture incorporated in the Netherlands operating 22 manufacturing facilities across 14 regions. Kimberly-Clark, retaining a 49% stake and the option for Suzano to purchase it later, is restructuring to focus on more profitable segments like personal care and North American tissue amid weak sales. The deal excludes Kimberly-Clark's U.S. consumer tissue and professional businesses, as well as interests in existing joint ventures in Mexico, South Korea, and Bahrain.

Analysis

Kimberly-Clark (KMB) is divesting a 51% majority stake in its international tissue business to Brazilian pulp producer Suzano (SUZ) for approximately $1.73 billion in cash, a deal that values the entire international tissue operation at $3.4 billion. This transaction, structured as a strategic joint venture incorporated in the Netherlands and expected to close by mid-2026, will result in Kimberly-Clark retaining a 49% interest, with Suzano gaining an option to acquire this remaining stake at a later date subject to certain conditions. The new joint venture will operate 22 manufacturing facilities across 14 regions, including Europe, Asia, the Middle East, and Central America. This divestiture represents a key component of Kimberly-Clark's strategy to address weak sales by reorganizing its businesses, simplifying operations, cutting costs, and concentrating on more profitable areas such as its personal care division and North American tissue segments. Kimberly-Clark will retain its U.S. consumer tissue and professional businesses, as well as its interests in existing joint ventures in Mexico, South Korea, and Bahrain. The moderately positive sentiment score of 0.6 for both KMB and SUZ suggests that the market perceives this strategic move favorably, supporting Kimberly-Clark's aim to improve its fundamental business outlook.

Key Decisions for Investors

• Investors should assess Kimberly-Clark's improved strategic focus on its core personal care and North American tissue segments following this divestiture, which is anticipated to generate $1.73 billion in cash by mid-2026.
• Monitor Kimberly-Clark's deployment of the transaction proceeds and the execution of its broader restructuring plan aimed at enhancing operational efficiency and addressing recent sales weaknesses.
• Evaluate the potential long-term value from KMB's retained 49% stake in the international tissue joint venture, considering Suzano's option for a future buyout and the de-risking of KMB's direct exposure to these international operations.